Merck opens USD 550 million lab. Merck & Co. stock falls 4.03 percent.

Published on 10/16/2026 at 09:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 sales reached USD 16.61 billion. Merck & Co. stock costs EUR 129.21 on October 16, 2026 versus the EUR 134.64 Xetra close.

Research investment and key dates

Merck inaugurated a USD 550 million ADVANCE facility on October 14, 2026.
Second-quarter 2026 sales reached USD 16.61 billion.
Merck & Co. stock trades at EUR 129.21 at 8:57 a.m. CEST at Lang & Schwarz on October 16, 2026, 4.03 percent below the Xetra close of October 15, 2026.
Third-quarter results are scheduled for October 29, 2026.

Isometric 3D illustration cutaway of a pharmaceutical manufacturing plant. Four interconnected zones show synthesis reactors with steel piping, a rotary tablet press with conveyor belts, a blister packaging line with foil sealing machines, and a pallet wa — Merck US58933Y1055 Pharma-Werk isometrisch: Reaktor, Wirkstoff-Synthese, Tablettenpresse, Verpackungslinie und Logistik-Lager im Querschnitt, Illustration mit AI erstellt.

Merck & Co. (ISIN US58933Y1055) was at EUR 129.21 at Lang & Schwarz on October 16, 2026 at 8:57 a.m. CEST, down 4.03 percent versus the Xetra close of October 15, 2026 at EUR 134.64. The company inaugurated a USD 550 million research facility in Pennsylvania on October 14, according to Merck.com.

ADVANCE puts research spending first

The ADVANCE facility at Merck's West Point campus uses robotics and digital artificial intelligence tools to analyze biological samples from clinical development programs. Merck said on October 14 that the project forms part of a previously announced USD 70 billion commitment to domestic manufacturing and research and development, while the Pennsylvania facilities represent USD 550 million of investment.

The scale of the project gives the announcement a long-term operating angle, but it does not change near-term earnings on its own. Merck has invested more than USD 15 billion at the West Point site over the past 35 years, according to Merck.com.

What will results say about growth?

Merck's second-quarter 2026 sales reached USD 16.61 billion, while operating profit was negative USD 584.0 million and the operating margin was negative 4.00 percent. The figures show why the next earnings update matters more for valuation than the facility opening. Merck will report its third-quarter 2026 results on October 29 at 9:00 a.m. ET, as stated by Merck.com.

Three dates frame the pipeline

On October 10, Merck presented one-year results from the BRUNELLO study, and on October 13 it showcased first-time pivotal phase 3 oncology results alongside more than 90 additional abstracts across more than 20 tumor types, according to Merck.com. The current event is the October 14 ADVANCE inauguration with its USD 550 million investment.

The next substantiated dates are October 26 for Merck's investor event at ESMO 2026 and October 29 for third-quarter sales and earnings. Both dates are listed on Merck & Co.'s investor-relations page.

Stock valuation meets a pipeline test

Citigroup raised its Merck price target from USD 125.00 to USD 145.00 while retaining a Neutral rating on October 12, according to Markets Insider. The counterweight is execution risk: the company must convert research spending and oncology data into sales growth while the latest quarter still showed a negative operating result.

Price points to a cautious session

Merck & Co. stock was trading at EUR 129.21 at Lang & Schwarz on October 16, 2026 at 8:57 a.m. CEST, 4.03 percent below the Xetra close of October 15, 2026 at EUR 134.64. The primary listing is on the NYSE, where the stock was last quoted at USD 145.35 on October 15, 2026 at 4:00 p.m. ET.

The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.